PMC

Time course of HCV-RNA load and HCV-antibody titer. (a) HCV-RNA load was elevated after treatment with rituximab or a chemotherapy regimen containing rituximab. (b) HCV-RNA load was elevated and HCV-antibody titer was decreased after rituximab and CHO. (c) HCV-RNA load was elevated after rituximab-containing regimen and decreased after chemotherapy without rituximab. HCV-antibody titer was decreased after rituximab-containing regimen. (d) HCV-RNA load was elevated after rituximab-containing regimen.